We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




GE Acquires Elscint's Share of ELGEMS

By HospiMedica staff writers
Posted on 19 Jan 2001
GE Medical Systems (Waukesha, WI, USA) has acquired the 50% interest of Elscint Ltd. (Haifa, Israel) in ELGEMS, a joint venture formed by GE and Elscint in 1997 to manufacture nuclear imaging systems. As a result, ELGEMS becomes a wholly owned GE business. The transaction reaffirms GE's commitment to the field of nuclear medicine as well as its Center of Excellence in Isreal, says the company.

ELGEMS, also based in Haifa, is responsible for the research, development, engineering, and manufacturing of all GE Medical gamma cameras and other nuclear imaging and positron emission tomography (PET) products. GE Medical and Elscint pioneered the development of the Hawkeye imaging system, which combined the anatomic delineation of computed tomography (CT) with the functional imaging capabilities of nuclear medicine. Under the terms of a new sourcing agreement, Elscint will continue to act as the primary source for the various components used in ELGEMS nuclear imaging products.

"ELGEMS has contributed significantly to GE Medical's nuclear imaging business,” said Beth Klein, vice president and general manager of nuclear medicine for GE medical. "The strategic supply agreement with Elscint has played a role in our success.”



Related Links:
GE Medical Systems
High-Precision QA Tool
DEXA Phantom
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Digital Color Doppler Ultrasound System
MS22Plus
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro

Channels

Nuclear Medicine

view channel
Image: This artistic representation illustrates how the drug candidate NECT-224 works in the human body (Photo courtesy of HZDR/A. Gruetzner)

Radiopharmaceutical Molecule Marker to Improve Choice of Bladder Cancer Therapies

Targeted cancer therapies only work when tumor cells express the specific molecular structures they are designed to attack. In urothelial carcinoma, a common form of bladder cancer, the cell surface protein... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.